vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and Nutex Health, Inc. (NUTX). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $151.7M, roughly 1.2× Nutex Health, Inc.). Nutex Health, Inc. runs the higher net margin — 7.8% vs 0.9%, a 6.9% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs -41.1%). Nutex Health, Inc. produced more free cash flow last quarter ($69.0M vs $16.0M). Over the past eight quarters, Nutex Health, Inc.'s revenue compounded faster (50.0% CAGR vs 29.5%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
FOLD vs NUTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $151.7M |
| Net Profit | $1.7M | $11.8M |
| Gross Margin | 85.7% | 30.4% |
| Operating Margin | 8.6% | 20.4% |
| Net Margin | 0.9% | 7.8% |
| Revenue YoY | 23.7% | -41.1% |
| Net Profit YoY | -88.5% | -80.8% |
| EPS (diluted) | $0.00 | $2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.2M | $151.7M | ||
| Q3 25 | $169.1M | $267.8M | ||
| Q2 25 | $154.7M | $244.0M | ||
| Q1 25 | $125.2M | $211.8M | ||
| Q4 24 | $149.7M | $257.6M | ||
| Q3 24 | $141.5M | $78.8M | ||
| Q2 24 | $126.7M | $76.1M | ||
| Q1 24 | $110.4M | $67.5M |
| Q4 25 | $1.7M | $11.8M | ||
| Q3 25 | $17.3M | $55.4M | ||
| Q2 25 | $-24.4M | $-17.7M | ||
| Q1 25 | $-21.7M | $21.2M | ||
| Q4 24 | $14.7M | $61.6M | ||
| Q3 24 | $-6.7M | $-8.8M | ||
| Q2 24 | $-15.7M | $-364.0K | ||
| Q1 24 | $-48.4M | $-364.0K |
| Q4 25 | 85.7% | 30.4% | ||
| Q3 25 | 88.5% | 57.8% | ||
| Q2 25 | 90.2% | 51.2% | ||
| Q1 25 | 90.7% | 55.9% | ||
| Q4 24 | 90.1% | 55.0% | ||
| Q3 24 | 90.6% | 27.8% | ||
| Q2 24 | 91.1% | 29.7% | ||
| Q1 24 | 87.7% | 15.1% |
| Q4 25 | 8.6% | 20.4% | ||
| Q3 25 | 20.3% | 48.7% | ||
| Q2 25 | -6.1% | 13.8% | ||
| Q1 25 | -6.3% | 38.1% | ||
| Q4 24 | 10.7% | 44.4% | ||
| Q3 24 | 15.3% | 12.3% | ||
| Q2 24 | 11.8% | 7.0% | ||
| Q1 24 | -25.1% | 2.1% |
| Q4 25 | 0.9% | 7.8% | ||
| Q3 25 | 10.2% | 20.7% | ||
| Q2 25 | -15.8% | -7.3% | ||
| Q1 25 | -17.3% | 10.0% | ||
| Q4 24 | 9.8% | 23.9% | ||
| Q3 24 | -4.8% | -11.2% | ||
| Q2 24 | -12.4% | -0.5% | ||
| Q1 24 | -43.9% | -0.5% |
| Q4 25 | $0.00 | $2.34 | ||
| Q3 25 | $0.06 | $7.76 | ||
| Q2 25 | $-0.08 | $-2.95 | ||
| Q1 25 | $-0.07 | $3.33 | ||
| Q4 24 | $0.05 | $11.56 | ||
| Q3 24 | $-0.02 | $-1.72 | ||
| Q2 24 | $-0.05 | $-0.07 | ||
| Q1 24 | $-0.16 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $185.6M |
| Total DebtLower is stronger | $392.7M | — |
| Stockholders' EquityBook value | $274.2M | $329.4M |
| Total Assets | $949.9M | $918.5M |
| Debt / EquityLower = less leverage | 1.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $293.5M | $185.6M | ||
| Q3 25 | $263.8M | $166.0M | ||
| Q2 25 | $231.0M | $96.7M | ||
| Q1 25 | $250.6M | $84.7M | ||
| Q4 24 | $249.9M | $40.6M | ||
| Q3 24 | $249.8M | $46.9M | ||
| Q2 24 | $260.1M | $40.8M | ||
| Q1 24 | $239.6M | $30.0M |
| Q4 25 | $392.7M | — | ||
| Q3 25 | $392.0M | — | ||
| Q2 25 | $391.3M | — | ||
| Q1 25 | $390.7M | — | ||
| Q4 24 | $390.1M | — | ||
| Q3 24 | $389.5M | — | ||
| Q2 24 | $388.9M | — | ||
| Q1 24 | $388.4M | — |
| Q4 25 | $274.2M | $329.4M | ||
| Q3 25 | $230.4M | $317.2M | ||
| Q2 25 | $204.3M | $235.3M | ||
| Q1 25 | $193.6M | $176.9M | ||
| Q4 24 | $194.0M | $132.4M | ||
| Q3 24 | $178.8M | $60.4M | ||
| Q2 24 | $132.5M | $62.7M | ||
| Q1 24 | $130.7M | $63.0M |
| Q4 25 | $949.9M | $918.5M | ||
| Q3 25 | $868.8M | $964.5M | ||
| Q2 25 | $815.3M | $841.0M | ||
| Q1 25 | $789.8M | $761.9M | ||
| Q4 24 | $785.0M | $655.3M | ||
| Q3 24 | $786.6M | $438.5M | ||
| Q2 24 | $749.5M | $422.4M | ||
| Q1 24 | $721.8M | $404.3M |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.02× | — | ||
| Q4 24 | 2.01× | — | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 2.93× | — | ||
| Q1 24 | 2.97× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $70.4M |
| Free Cash FlowOCF − Capex | $16.0M | $69.0M |
| FCF MarginFCF / Revenue | 8.6% | 45.5% |
| Capex IntensityCapex / Revenue | 0.2% | 0.9% |
| Cash ConversionOCF / Net Profit | 9.62× | 5.95× |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | $245.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.3M | $70.4M | ||
| Q3 25 | $35.7M | $99.5M | ||
| Q2 25 | $-26.5M | $27.3M | ||
| Q1 25 | $7.8M | $51.0M | ||
| Q4 24 | $-3.9M | $54.0K | ||
| Q3 24 | $-23.0M | $6.8M | ||
| Q2 24 | $22.7M | $13.3M | ||
| Q1 24 | $-29.7M | $3.1M |
| Q4 25 | $16.0M | $69.0M | ||
| Q3 25 | $35.3M | $99.2M | ||
| Q2 25 | $-28.9M | $26.5M | ||
| Q1 25 | $7.5M | $50.9M | ||
| Q4 24 | $-4.2M | $-341.0K | ||
| Q3 24 | $-23.3M | $6.2M | ||
| Q2 24 | $21.6M | $12.7M | ||
| Q1 24 | $-31.5M | $2.3M |
| Q4 25 | 8.6% | 45.5% | ||
| Q3 25 | 20.9% | 37.0% | ||
| Q2 25 | -18.7% | 10.9% | ||
| Q1 25 | 6.0% | 24.0% | ||
| Q4 24 | -2.8% | -0.1% | ||
| Q3 24 | -16.5% | 7.8% | ||
| Q2 24 | 17.0% | 16.7% | ||
| Q1 24 | -28.5% | 3.4% |
| Q4 25 | 0.2% | 0.9% | ||
| Q3 25 | 0.2% | 0.1% | ||
| Q2 25 | 1.6% | 0.3% | ||
| Q1 25 | 0.2% | 0.0% | ||
| Q4 24 | 0.2% | 0.2% | ||
| Q3 24 | 0.3% | 0.8% | ||
| Q2 24 | 0.9% | 0.7% | ||
| Q1 24 | 1.6% | 1.1% |
| Q4 25 | 9.62× | 5.95× | ||
| Q3 25 | 2.06× | 1.80× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 2.40× | ||
| Q4 24 | -0.27× | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
